ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TSTL Tristel Plc

465.00
2.50 (0.54%)
Last Updated: 12:24:46
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.50 0.54% 465.00 460.00 470.00 465.00 462.50 462.50 20,697 12:24:46
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 36.01M 4.46M 0.0941 49.42 220.41M
Tristel Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 462.50p. Over the last year, Tristel shares have traded in a share price range of 327.50p to 499.00p.

Tristel currently has 47,400,993 shares in issue. The market capitalisation of Tristel is £220.41 million. Tristel has a price to earnings ratio (PE ratio) of 49.42.

Tristel Share Discussion Threads

Showing 1876 to 1900 of 4000 messages
Chat Pages: Latest  76  75  74  73  72  71  70  69  68  67  66  65  Older
DateSubjectAuthorDiscuss
25/4/2015
16:41
Pity, I have an increase price at 70p :-(
apad

apad
25/4/2015
16:40
IC:
Clean up with Tristel
Each year, a staggering 300,000 NHS patients pick up infections while being treated at hospitals in England. Part of the NHS response to this has been to recommend the disinfectant products of Aim-traded
Tristel (TSTL), which are now supplied to around 700 public and private hospitals in the UK.
The company’s main technology is its patented chlorine dioxide formulation, a highly effective disinfectant that can kill C.difficile spores in 30 seconds. In addition to hospitals – which account for 86 per cent of turnover – Tristel’s sprays, gels, foams, liquids and other products are used to clean surfaces and instruments in pharmaceutical clean rooms and veterinary practices. A skin-friendly product has also been developed and is being rolled out, pending some regulatory hurdles.
Tristel floated in 2005 and now boasts real sales momentum. It has generated record revenues in each of the past four six-month trading periods, and in the final half of 2014 grew sales by 15 per cent to £7.4m, in line with a sales goal of £20m by 2016-17. In the UK, which accounts for two-thirds of revenue, the key to sales growth is improving ties to hospitals’ infection control teams and targeting specialisations such as cardiology and ophthalmology, where adoption of Tristel’s products is less widespread.
Increased scale has helped widen net margins, which are forecast to increase by 150 basis points to 15 per cent in the financial year to the end of June. This is leading to rapid EPS growth, which should also support forecasts of dividend increases. The shares should reward investors with a 3.8 per cent yield next year. And it’s not only the shares’ yield that represents attractive value. Tristel’s enterprise value is 12 times forecast operating profit, and 1.8 times this year’s expected sales. Based on these valuation measures, Tristel is valued at a discount to the sector of a quarter and a third, respectively.
Part of the reason for this discount may be the company’s reliance on one main scientific area, and the risk posed if a new disinfectant technology supersedes Tristel’s brands. However, recurring revenues of 96 per cent should help to calm any nerves about the resilience of the business model, as should the fact that Tristel sells to more than 40 countries.
One potentially game-changing country Tristel does not sell to at the moment is the US, despite considerable interest in the company’s products from clinicians across the pond. FDA approval of the company’s products could come within two to three years, according to analysts at Equity Development, providing access to the largest healthcare market in the world along with major potential for a re-rating of the shares. Management is understandably keen not to overplay the prospect of US expansion, although it remains a strategic priority, as does growth in Europe. In both cases, regulatory costs will eat into profits. But this is factored into the forecasts in our table and more than outweighed by the potential upside.
Tristel’s shares have done well since 2013 and there is serious momentum in the growth story. The price-to-earnings-growth (PEG) ratio of 0.8 is only half the sector average and, at below one, suggests earnings growth is being seriously undervalued. Buy. AN

apad
24/4/2015
08:27
thank jimmy. Good news
gswredland
24/4/2015
08:07
Reminder of the interim results:

Financial highlights

-- Revenue up 15% to GBP7.4m (2013: GBP6.4m)
-- International sales up 26% to GBP2.4m (2013: GBP1.9m)
-- Pre-tax profit before share based payments up 57% to GBP1.1m (2013: GBP0.7m)
-- EBITDA up 25% to GBP1.5m (2013: GBP1.2m)
-- Basic EPS up 85% to 1.91p (2013: 1.03p)
-- Interim dividend of 0.585p per share (2013: 0.36p), an increase of 63%
-- Cash generative, with net cash at period end of GBP2.9m (2013: GBP1.5m)

rcturner2
23/4/2015
20:34
IC tip of the week They say earnings growth is being seriously undervalued. Buy.
jimmygee2
22/4/2015
14:13
Tristel ‏@Tristeluk
Visit our Belgian Distributor @EcomedServices exhibiting @VHIGcongres to learn about our new Tristel Trace System!

piedro
21/4/2015
15:44
APAD,
Interesting arguments.
Are you implying that this is a dodgy and unreliable share?

piedro
18/4/2015
10:59
I have an "increaase" price set at 70p, G. I think P's position, above, is emminently sensible. However, the trouble with small caps is that as soon as a view is accepted the price has moved, so one has to anticipate the position. The recovery trajectory finished in June last year and the share price has gone nowhere in particular since then. So, the next leg will be up or down depending on results. My view is that the management have proved themselves since exiting the endoscope market and that it is worth anticipating good results in the summer when the share price is at the bottom of its oscillation.
This is with the caveat that I would limit the holding to 2% of my portfolio (nothing is above 10%).
apad

apad
15/4/2015
19:35
Tristel will be exhibiting at the Mello investor workshop event next week so you can meet the directors then www.melloevents.com/mello-workshop/
davidosh
15/4/2015
16:26
Mach100,

Re: the stickers
I prefer to bathe my animals with shampoo + tick pouron
And believe a healthy country life is better than living
in a kennel.

Cheers.

piedro
15/4/2015
16:16
Good luck Gostevie63.

I find the brokers EPS for Jun 2015 of 4.01-4.20p a bit advanced and prefer c.3.80p as more conservative, but if proved wrong will gladly accept that recovery has now become sustainable growth and a PE of 22 less risky.

AIMHO, BWDIK

piedro
15/4/2015
15:43
Greetings fellow Tristel holders. I bought-in today at 71.4p (including costs). Did my own research after reading THEwheeliedealer's blog last week and liked what I saw.
gostevie63
15/4/2015
13:15
How many stickers have you accumulated so far, Piedro? Bid has fallen to 69p now but hopefully we can move back up again in short order. Might be due to the popularity of the above prizes :P
mach100
14/4/2015
14:16
A give-away ...

Anisteluk ‏@anisteluk
Heard about Anistel's #Loyalty Scheme...?Collect stickers on caps of Anistel 5L Surface Disinfectant to claim prizes!

piedro
12/4/2015
09:17
I found this before the advert above and can recommend it.
apad

apad
11/4/2015
21:12
Hi all,

I have a few TSTL and did a detailed Blog on them this week with Overview, Risks, Valuation, Targets etc. and some Charts - check it out here:



I expect to be holding these for a good few years and the upside here looks pretty attractive. Seems like a business that is really on a Roll..

cheers, WheelieD

thewheeliedealer
10/4/2015
15:05
Anisteluk ‏@anisteluk
"Another great day at Anistel Stand 607!"

piedro
09/4/2015
15:05
BSAVA2015 - Stand 607
piedro
08/4/2015
09:53
A new gimmick ...



Pure Hold Hygiene Handle - a unique, revolutionary pull door handle that automatically dispenses sanitising gel
The Pure Hold Hygiene Handle is ideal for use in food processing plants, hospitals, clean rooms and all staff/ public toilets to ensure that hand hygiene is enforced. ....


- I expect Tristel to do one better than the competition

piedro
08/4/2015
09:44
We're still awaiting confirmation of "sustainable recovery"
and the 'Revolver' launch
AIMO

piedro
08/4/2015
08:32
*boing* here's hoping we break the sideways pattern with this one
rufio90210
04/4/2015
20:28
We have our Mello Workshops event just three weeks away and I am pleased to say that Tristel will have a stand at our event. There will be lots of investor educational workshops to attend and great speakers.

If you are keen on small caps and quality companies where you will be able to meet the directors then you should come to the Mello investor workshops event as we will have at least 30 coming to Peterborough and we have just released the first list ......

davidosh
02/4/2015
19:52
It could easily go into the 60s, seen all sorts of funny share price movements over the years. Check out Amino Tech, which inexplicably dropped to 80p at one point, now about 140p.
rcturner2
02/4/2015
14:19
But maybe shorter than the wait for 69.875p?
effortless cool
02/4/2015
13:55
Gonna be a long wait then
metier9
Chat Pages: Latest  76  75  74  73  72  71  70  69  68  67  66  65  Older

Your Recent History

Delayed Upgrade Clock